
Medline Faces Securities Fraud Probe After Product Quality Failures
A 13 percent single-day stock plunge on August 5, 2026, has triggered a formal securities fraud investigation into Medline Inc. The inquiry, led by the law firm Bleichmar Fonti & Auld LLP, examines whether the healthcare giant misled investors regarding its internal manufacturing standards and product quality controls.


























